PF-00446687 + Placebo

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Female Sexual Dysfunction

Conditions

Female Sexual Dysfunction

Trial Timeline

Jun 1, 2007 → Feb 1, 2008

About PF-00446687 + Placebo

PF-00446687 + Placebo is a phase 2 stage product being developed by Pfizer for Female Sexual Dysfunction. The current trial status is completed. This product is registered under clinical trial identifier NCT00479570. Target conditions include Female Sexual Dysfunction.

What happened to similar drugs?

2 of 15 similar drugs in Female Sexual Dysfunction were approved

Approved (2) Terminated (0) Active (13)

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00479570Phase 2Completed

Competing Products

20 competing products in Female Sexual Dysfunction

See all competitors
ProductCompanyStageHype Score
FulvestrantDr. Reddy's LaboratoriesPre-clinical
19
Fulvestrant + AbemaciclibEli LillyPhase 2
39
Gemcitabine + liposomal doxorubicinEli LillyPhase 3
40
ASP3325 + PlaceboAstellas PharmaPhase 1
29
EnsitrelvirShionogiPhase 1
29
Eribulin Injection [Halaven] + Paclitaxel injectionEisaiApproved
39
Gemcitabine + Paclitaxel + CarboplatinEli LillyPhase 3
40
Abemaciclib 50 MG; 150mg 1-0-1 per osEli LillyPhase 3
44
Abemaciclib, durvalumab and aromatase inhibitorEli LillyPhase 1
21
norelgestromin/ethinyl estradiol (NGMN/EE) transdermal contraceptive system.Johnson & JohnsonPhase 1
29
Norgestimate/Ehinyl Estradiol; Folic acid.Johnson & JohnsonPhase 1
29
SHR6390 + placeboJiangsu Hengrui MedicinePhase 3
44
SHR7280 tabletsJiangsu Hengrui MedicinePhase 2
35
SHR7280;Ganirelix Acetate Injection simulant + SHR7280 simulant; Ganirelix Acetate InjectionJiangsu Hengrui MedicinePhase 3
40
SHR3162Jiangsu Hengrui MedicinePhase 1
25
AZD3293 + PlaceboAstraZenecaPhase 1
29
Fulvestrant 500mg + Palbociclib 125mg + Goserelin 3.6 MG + PlacebosAstraZenecaPhase 3
40
AZD2516 + PlaceboAstraZenecaPhase 1
29
Durvalumab + TremelimumabAstraZenecaPhase 2
39
Dapagliflozin + Metformin + Dapagliflozin + MetforminAstraZenecaPhase 1
29